Option Care Health, Inc. (NASDAQ:OPCH) Q1 2024 Earnings Conference Call April 23, 2024 8:30 AM ET

Company Participants

Mike Shapiro - Chief Financial Officer
John Rademacher - President & Chief Executive Officer

Conference Call Participants

Jack Slevin - Jefferies
David MacDonald - Truist Securities
Lisa Gill - JPMorgan
Matthew Larew - William Blair
Pito Chickering - Deutsche Bank
Michael Petusky - Barrington Research
Joanna Gajuk - Bank of America

Operator

Good day and thank you for standing by. Welcome to the Option Care Health Q1 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker, Mike Shapiro, Chief Financial Officer. Please go ahead.

Mike Shapiro

Good morning. Please note that today's discussion will include certain forward-looking statements that reflect our current assumptions and expectations, including those related to our future financial performance and industry and market conditions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. We encourage you to review the information in today's press release as well as in our Form 10-K filed with the SEC regarding the specific risks and uncertainties. We do not undertake any duty to update any forward-looking statements, except as required by law. During the call, we will use non-GAAP financial measures when talking about the company's performance and financial condition. You can find additional information on these non-GAAP measures in this morning's press release posted on the Investor Relations portion of our website.

And with that, I'll turn the call over to John Rademacher, Chief Executive Officer.

John Rademacher

Thanks, Mike and good morning, everyone. As always, I'd like to share a few thoughts upfront on the performance of the enterprise as well as the quarter before handing the call back over to Mike to dive into the financial results a bit deeper.

Overall, the first quarter was very solid start to the year despite some of the challenges we recently disclosed regarding the Change Healthcare situation which I will expand upon in a moment. Revenue growth of over 12% reflects the dedication of the more than 7,500 team members who are committed to an unparalleled patient care and finding a way to serve more patients.

We saw a solid top line growth with considerable contribution from a number of the newer chronic therapies launched over the past year. The team is consistently executing across the country and across relationships with key stakeholders, including payers, referring physicians, hospital and health system teams as well as our pharma partners and while we are proud of the top line results in the quarter, we are equally as proud that our patient satisfaction remains quite strong in the quarter at 93% with a Net Promoter Score of 76.2.